fumagillin


Also found in: Encyclopedia, Wikipedia.

fumagillin

(fū″mă-jĭl′ĭn)
A molecule produced by fungi that prevents new blood vessel formation (“angiogenesis”), and may be useful in treating cancers.

fumagillin

an antibiotic produced by Aspergillus fumigatus. Used in bees to control the parasite, Nosema.
References in periodicals archive ?
Conjugation of our novel fumagillin 'warhead' to Fleximer using a specific linker technology reduces CNS exposure in animal models to below detection limits.
Hughes will discuss results from the preclinical study, which evaluated short-term treatment with fumagillin in obese mice on ERK phosphorylation and key downstream effector genes relevant to the control of fat metabolism.
Our preclinical studies have demonstrated that the Fleximer-linked drug XMT-1107 offers key important potential benefits over other fumagillin analogs that have undergone clinical trials.
Fumagillin analogs had been shown to have anti-tumor activity in Phase 1 and 2 trials, but development was discontinued due to pharmacokinetic (PK) issues and reversible central nervous system (CNS) toxicity observed in patients.
FUMAGILLIN MANUFACTURERS AND TRADERS OF FUMAGILLIN (INCLUDING CONTACT DETAILS)
E[acute accent]PPI-2458 is a novel, proprietary small molecule belonging to the fumagillin class of compounds that specifically targets the methionine aminopeptidase-2 (MetAP-2) enzyme.
Louis, was published in a paper entitled, "Endothelial alpha-v-beta-3 Integrin-Targeted Fumagillin Nanoparticles Inhibit Angiogenesis in Atherosclerosis" (Winter, et al) in the September issue of the journal Arteriosclerosis, Thrombosis, and Vascular Biology.
PPI-2458 is a novel, proprietary molecule belonging to the fumagillin class of compounds that specifically targets the MetAP-2 enzyme.
PPI-2458 is a novel, proprietary molecule based on the fumagillin class of compounds that have been shown to prevent both abnormal cell growth and the formation of new blood vessels, which contribute to aberrant tissue growth.
PPI-2458 is a novel, proprietary molecule based on the fumagillin class of compounds that have been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as anti-angiogenesis), which contribute to the growth of aberrant tissues in diseases such as cancer and Rheumatoid Arthritis (RA).
6,548,477 was issued on April 15, 2003 covering a family of fumagillin analogs, including PPI-2458.